# Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

> **NCT01164267** · PHASE2 · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 30 (actual)

## Conditions studied

- Marginal Zone B-cell Lymphoma

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01164267
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164267, "Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01164267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*